

Multimedia Appendix 4

Codebook for all surveys

Includes all branching logic.

#	Variable / Field Name	Field Label <i>Field Note</i>	Field Attributes (Field Type, Validation, Choices, Calculations, etc.)
Instrument: Learning Style Survey			
1	record_id	Record ID	text
2	introduction	<p>The My Cancer Genome team at Vanderbilt-Ingram Cancer Center (VICC) is conducting a study to improve cancer genetics web pages for oncology physicians and nurses. You are invited to participate in this oncology education program and survey about the concepts of sensitivity and resistance to targeted therapies for ER+ breast cancer.</p> <p>Here's how it works: -- Answer a question about your preferred learning format and take a 10-question pre-test. -- Take a look at the educational materials and answer a few questions. -- In two weeks, answer a few follow-up questions, and fill out a form to receive your \$100 Amazon.com Gift Card.*</p> <p>Participating will take about 30 minutes. Your participation is totally voluntary and all responses will be confidential. There is very low risk to participating in this survey. You can choose not to answer all of the questions.</p> <p>Thank you so much for participating. If you have questions or comments contact us via email at mialevy.mycancergenome@vanderbilt.edu or by phone by calling Christine Micheel, Ph.D. (study coordinator and My</p>	descriptive

		<p>Cancer Genome managing editor), at 615-933-9368.</p> <p>Thank you,</p> <p>Mia Levy, MD, PhD</p> <p>Co-Editor in Chief, My Cancer Genome Assistant Professor of Biomedical Informatics and Medicine Vanderbilt University Medical Center 2220 Pierce Avenue 691 Preston Research Building Nashville, TN 37232-6838</p>					
3	pin_number	<p>What is the PIN number from your invitation email? <i>This 10-character code can be found in your invitation email. It is case sensitive. Please note that entries associated with incorrect PIN numbers will be ineligible for the \$100 Amazon gift card.</i></p>	text, Required				
4	email	<p>What is your email address? <i>Your email is required to complete the study and for your gift card. Your email will not be used for anything other than the study or after completion of the study.</i></p>	text (email), Required, Identifier				
5	consent	<p>I agree to participate in this study.</p>	<p>yesno, Required</p> <table border="1"> <tr> <td>1</td> <td>Yes</td> </tr> <tr> <td>0</td> <td>No</td> </tr> </table> <p>Stop actions on 0</p>	1	Yes	0	No
1	Yes						
0	No						
6	amazon_disclaimer_1	<p>*Amazon.com is not a sponsor of this promotion. Except as required by law, Amazon.com Gift Cards ("GCs") cannot be transferred for value or redeemed for cash. GCs may be used only for purchases of eligible goods at Amazon.com or certain of its affiliated websites. For complete terms and conditions, see www.amazon.com/gc-legal. GCs are issued by ACI Gift</p>	descriptive				

		Cards, Inc., a Washington corporation. All Amazon ®, ™ & © are IP of Amazon.com, Inc. or its affiliates. No expiration date or service fees.															
7	active_practice	Are you actively practicing in an oncology setting?	yesno, Required <table border="1"> <tr> <td>1</td> <td>Yes</td> </tr> <tr> <td>0</td> <td>No</td> </tr> </table>	1	Yes	0	No										
1	Yes																
0	No																
8	goodbye Show the field ONLY if: [active_practice] = '0'	Only individuals actively practicing in an oncology setting are eligible to participate in this study. Thank you for your interest.	descriptive														
9	role_description Show the field ONLY if: [active_practice] = '1'	Which of the following best describes you?	radio <table border="1"> <tr> <td>1</td> <td>Physician</td> </tr> <tr> <td>2</td> <td>Physician Assistant</td> </tr> <tr> <td>3</td> <td>Nurse</td> </tr> <tr> <td>4</td> <td>Genetic Counselor</td> </tr> <tr> <td>5</td> <td>Allied Health Provider</td> </tr> <tr> <td>6</td> <td>Other</td> </tr> </table>	1	Physician	2	Physician Assistant	3	Nurse	4	Genetic Counselor	5	Allied Health Provider	6	Other		
1	Physician																
2	Physician Assistant																
3	Nurse																
4	Genetic Counselor																
5	Allied Health Provider																
6	Other																
10	other_role Show the field ONLY if: [role_description] = '6'	Please explain:	text														
11	physician_specialty Show the field ONLY if: [role_description] = '1'	Which of the following best describes you?	radio <table border="1"> <tr> <td>1</td> <td>Resident</td> </tr> <tr> <td>2</td> <td>Fellow</td> </tr> <tr> <td>3</td> <td>Medical oncologist and/or hematologist</td> </tr> <tr> <td>4</td> <td>Surgical oncologist</td> </tr> <tr> <td>5</td> <td>Radiation oncologist</td> </tr> <tr> <td>6</td> <td>Pathologist</td> </tr> <tr> <td>7</td> <td>None of the above</td> </tr> </table>	1	Resident	2	Fellow	3	Medical oncologist and/or hematologist	4	Surgical oncologist	5	Radiation oncologist	6	Pathologist	7	None of the above
1	Resident																
2	Fellow																
3	Medical oncologist and/or hematologist																
4	Surgical oncologist																
5	Radiation oncologist																
6	Pathologist																
7	None of the above																
12	md_none_of_the_above Show the field ONLY if: [physician_specialty] = '7'	If you marked none of the above, please explain.	text														
13	residency_fellowship Show the field ONLY if: [role_description] = '1'	How many years has it been since you completed residency/fellowship?	radio <table border="1"> <tr> <td>1</td> <td>Less than 5</td> </tr> <tr> <td>2</td> <td>5-9</td> </tr> <tr> <td>3</td> <td>10-15</td> </tr> <tr> <td>4</td> <td>Greater than 15</td> </tr> </table>	1	Less than 5	2	5-9	3	10-15	4	Greater than 15						
1	Less than 5																
2	5-9																
3	10-15																
4	Greater than 15																

			5 N/A														
14	learning_styles Show the field ONLY if: [active_practice] = '1'	I am likely to remember something a year from now if:	radio, Required <table border="1"> <tr><td>100</td><td>I learn it by reading</td></tr> <tr><td>010</td><td>I learn it by listening</td></tr> <tr><td>001</td><td>I learn it by watching</td></tr> <tr><td>110</td><td>I learn it by reading and listening</td></tr> <tr><td>101</td><td>I learn it by reading and watching</td></tr> <tr><td>011</td><td>I learn it by listening and watching</td></tr> <tr><td>111</td><td>I learn it by reading, listening, and watching</td></tr> </table>	100	I learn it by reading	010	I learn it by listening	001	I learn it by watching	110	I learn it by reading and listening	101	I learn it by reading and watching	011	I learn it by listening and watching	111	I learn it by reading, listening, and watching
100	I learn it by reading																
010	I learn it by listening																
001	I learn it by watching																
110	I learn it by reading and listening																
101	I learn it by reading and watching																
011	I learn it by listening and watching																
111	I learn it by reading, listening, and watching																
15	learning_style_survey_complete	Complete?	dropdown <table border="1"> <tr><td>0</td><td>Incomplete</td></tr> <tr><td>1</td><td>Unverified</td></tr> <tr><td>2</td><td>Complete</td></tr> </table>	0	Incomplete	1	Unverified	2	Complete								
0	Incomplete																
1	Unverified																
2	Complete																
Instrument: Knowledge Pre-Test																	
16	pretest_rb1	Phosphorylation of RB1 facilitates which of the following:	radio, Required <table border="1"> <tr><td>20</td><td>Tumor suppression</td></tr> <tr><td>21</td><td>Inhibition of cell cycle progression</td></tr> <tr><td>22</td><td>Entry into the S phase of the cell cycle</td></tr> <tr><td>23</td><td>Formation of a Cyclin D1-CDK4/6 complex</td></tr> <tr><td>100</td><td>Don't know</td></tr> </table>	20	Tumor suppression	21	Inhibition of cell cycle progression	22	Entry into the S phase of the cell cycle	23	Formation of a Cyclin D1-CDK4/6 complex	100	Don't know				
20	Tumor suppression																
21	Inhibition of cell cycle progression																
22	Entry into the S phase of the cell cycle																
23	Formation of a Cyclin D1-CDK4/6 complex																
100	Don't know																
17	pretest_acquired_definition	Acquired resistance to endocrine therapy in ER+ breast cancer is defined as recurrence at least 6-12 months after completion of adjuvant therapy or disease progression > 6 months after endocrine therapy initiated in the metastatic setting.	radio, Required <table border="1"> <tr><td>1</td><td>True</td></tr> <tr><td>0</td><td>False</td></tr> <tr><td>100</td><td>Don't know</td></tr> </table>	1	True	0	False	100	Don't know								
1	True																
0	False																
100	Don't know																
18	pretest_primary_definition	Please fill in the blank with the correct answer. Primary resistance to endocrine therapy in ER+ breast cancer has been defined as disease progression less than ____ months after treatment in the metastatic setting.	radio, Required <table border="1"> <tr><td>12</td><td>12</td></tr> <tr><td>10</td><td>10</td></tr> <tr><td>8</td><td>8</td></tr> <tr><td>6</td><td>6</td></tr> </table>	12	12	10	10	8	8	6	6						
12	12																
10	10																
8	8																
6	6																

			100	Don't know
19	pretest_estrogen	Estrogen is a steroid hormone that controls cell processes like cell division, growth, differentiation, and proliferation.	radio, Required	
			1	True
			0	False
			100	Don't know
20	pretest_primary_mechanisms	Which of the following is a way primary resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer may occur?	radio, Required	
			30	Estrogen receptor (ER) amplification
			31	Cyclin D1 amplification
			32	RB1 amplification
			300	None of the above
			100	Don't know
21	pretest_acquired_mechanisms	Which of the following are ways acquired resistance to endocrine therapy in ER+ breast may occur?	radio, Required	
			40	Activation of growth factor signaling pathways
			41	Changes in the tumor microenvironment
			42	Estrogen receptor mutations
			200	All of the above
			100	Don't know
22	pretest_fda_approved	Which drug combination is FDA-approved to treat ER+ metastatic breast cancer resistant to letrozole or anastrozole?	radio, Required	
			50	Everolimus + exemestane
			51	Erlotinib + exemestane
			52	Palbociclib + exemestane
			53	Bevacizumab + exemestane
			100	Don't know
23	pretest_cdk46_settings	CDK4/6 inhibitors have only been evaluated in the first line setting in breast cancer.	radio, Required	
			1	True
			0	False
			100	Don't know
24	pretest_fda_accelerated	The FDA granted accelerated approval of which of the following drug combinations for first line or initial endocrine therapy in postmenopausal women with ER+/HER2-negative advanced breast cancer?	radio, Required	
			60	Palbociclib + letrozole
			61	Erlotinib + letrozole
			62	Bevacizumab + letrozole
			63	Everolimus + letrozole

			<table border="1"> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	100	Don't know								
100	Don't know												
25	pretest_palbociclib	Palbociclib is in which of the following drug classes?	radio, Required <table border="1"> <tr> <td>70</td> <td>mTOR inhibitors</td> </tr> <tr> <td>71</td> <td>CDK4/6 inhibitors</td> </tr> <tr> <td>72</td> <td>PI3K inhibitors</td> </tr> <tr> <td>73</td> <td>EGFR inhibitors</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	70	mTOR inhibitors	71	CDK4/6 inhibitors	72	PI3K inhibitors	73	EGFR inhibitors	100	Don't know
70	mTOR inhibitors												
71	CDK4/6 inhibitors												
72	PI3K inhibitors												
73	EGFR inhibitors												
100	Don't know												
26	prelearning_material_review_survey_complete	Complete?	dropdown <table border="1"> <tr> <td>0</td> <td>Incomplete</td> </tr> <tr> <td>1</td> <td>Unverified</td> </tr> <tr> <td>2</td> <td>Complete</td> </tr> </table>	0	Incomplete	1	Unverified	2	Complete				
0	Incomplete												
1	Unverified												
2	Complete												
Instrument: Link to Learning Materials													
27	learning_materials_link	Please click on the link below to view your learning materials: Link to Learning Materials (http://www.mycancergenome.org/learning-material/?record=[enrollment_arm_1][record_id]&ls=[enrollment_arm_1][learning_styles]&pin=[enrollment_arm_1][pin_number]) When you are finished reviewing your learning materials, click the submit button below. You will be taken to a page with a link to the "Post-Learning Material Review Survey." You should also be receiving this link and a link to the next survey by email.	descriptive										
28	link_to_learning_materials_complete	Complete?	dropdown <table border="1"> <tr> <td>0</td> <td>Incomplete</td> </tr> <tr> <td>1</td> <td>Unverified</td> </tr> <tr> <td>2</td> <td>Complete</td> </tr> </table>	0	Incomplete	1	Unverified	2	Complete				
0	Incomplete												
1	Unverified												
2	Complete												
Instrument: Knowledge Post-Test													
29	posttest_palbociclib	Palbociclib is in which of the following drug classes?	radio, Required <table border="1"> <tr> <td>72</td> <td>PI3K inhibitors</td> </tr> </table>	72	PI3K inhibitors								
72	PI3K inhibitors												

			<table border="1"> <tr> <td>70</td> <td>mTOR inhibitors</td> </tr> <tr> <td>71</td> <td>CDK4/6 inhibitors</td> </tr> <tr> <td>73</td> <td>EGFR inhibitors</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	70	mTOR inhibitors	71	CDK4/6 inhibitors	73	EGFR inhibitors	100	Don't know		
70	mTOR inhibitors												
71	CDK4/6 inhibitors												
73	EGFR inhibitors												
100	Don't know												
30	posttest_cdk46_settings	CDK4/6 inhibitors have only been evaluated in the first line setting in breast cancer.	radio, Required <table border="1"> <tr> <td>1</td> <td>True</td> </tr> <tr> <td>0</td> <td>False</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	1	True	0	False	100	Don't know				
1	True												
0	False												
100	Don't know												
31	posttest_acquired_mechanisms	Which of the following are ways acquired resistance to endocrine therapy in ER+ breast may occur?	radio, Required <table border="1"> <tr> <td>42</td> <td>Estrogen receptor mutations</td> </tr> <tr> <td>40</td> <td>Activation of growth factor signaling pathways</td> </tr> <tr> <td>41</td> <td>Changes in the tumor microenvironment</td> </tr> <tr> <td>200</td> <td>All of the above</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	42	Estrogen receptor mutations	40	Activation of growth factor signaling pathways	41	Changes in the tumor microenvironment	200	All of the above	100	Don't know
42	Estrogen receptor mutations												
40	Activation of growth factor signaling pathways												
41	Changes in the tumor microenvironment												
200	All of the above												
100	Don't know												
32	posttest_acquired_definition	Acquired resistance to endocrine therapy in ER+ breast cancer is defined as recurrence at least 6-12 months after completion of adjuvant therapy or disease progression > 6 months after endocrine therapy initiated in the metastatic setting.	radio, Required <table border="1"> <tr> <td>1</td> <td>True</td> </tr> <tr> <td>0</td> <td>False</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	1	True	0	False	100	Don't know				
1	True												
0	False												
100	Don't know												
33	posttest_fda_approved	Which drug combination is FDA-approved to treat ER+ metastatic breast cancer resistant to letrozole or anastrozole?	radio, Required <table border="1"> <tr> <td>53</td> <td>Bevacizumab + exemestane</td> </tr> <tr> <td>50</td> <td>Everolimus + exemestane</td> </tr> <tr> <td>52</td> <td>Palbociclib + exemestane</td> </tr> <tr> <td>51</td> <td>Erlotinib + exemestane</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	53	Bevacizumab + exemestane	50	Everolimus + exemestane	52	Palbociclib + exemestane	51	Erlotinib + exemestane	100	Don't know
53	Bevacizumab + exemestane												
50	Everolimus + exemestane												
52	Palbociclib + exemestane												
51	Erlotinib + exemestane												
100	Don't know												
34	posttest_fda_accelerated	The FDA granted accelerated approval of which of the following drug combinations for first line or initial endocrine therapy in postmenopausal women with ER+/HER2-negative advanced breast cancer?	radio, Required <table border="1"> <tr> <td>63</td> <td>Everolimus + letrozole</td> </tr> <tr> <td>60</td> <td>Palbociclib + letrozole</td> </tr> <tr> <td>62</td> <td>Bevacizumab + letrozole</td> </tr> <tr> <td>61</td> <td>Erlotinib + letrozole</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	63	Everolimus + letrozole	60	Palbociclib + letrozole	62	Bevacizumab + letrozole	61	Erlotinib + letrozole	100	Don't know
63	Everolimus + letrozole												
60	Palbociclib + letrozole												
62	Bevacizumab + letrozole												
61	Erlotinib + letrozole												
100	Don't know												
35	posttest_primary_mechanisms	Which of the following is a way primary resistance to endocrine	radio, Required <table border="1"> <tr> <td>30</td> <td>Estrogen receptor (ER)</td> </tr> </table>	30	Estrogen receptor (ER)								
30	Estrogen receptor (ER)												

		therapy in estrogen receptor-positive (ER+) breast cancer may occur?	<table border="1"> <tr> <td></td> <td>amplification</td> </tr> <tr> <td>32</td> <td>RB1 amplification</td> </tr> <tr> <td>31</td> <td>Cyclin D1 amplification</td> </tr> <tr> <td>300</td> <td>None of the above</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>		amplification	32	RB1 amplification	31	Cyclin D1 amplification	300	None of the above	100	Don't know
	amplification												
32	RB1 amplification												
31	Cyclin D1 amplification												
300	None of the above												
100	Don't know												
36	posttest_estrogen	Estrogen is a steroid hormone that controls cell processes like cell division, growth, differentiation, and proliferation.	radio, Required <table border="1"> <tr> <td>1</td> <td>True</td> </tr> <tr> <td>0</td> <td>False</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	1	True	0	False	100	Don't know				
1	True												
0	False												
100	Don't know												
37	posttest_primary_definition	Please fill in the blank with the correct answer. Primary resistance to endocrine therapy in ER+ breast cancer has been defined as disease progression less than ____ months after treatment in the metastatic setting.	radio, Required <table border="1"> <tr> <td>8</td> <td>8</td> </tr> <tr> <td>6</td> <td>6</td> </tr> <tr> <td>12</td> <td>12</td> </tr> <tr> <td>10</td> <td>10</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	8	8	6	6	12	12	10	10	100	Don't know
8	8												
6	6												
12	12												
10	10												
100	Don't know												
38	posttest_rb1	Phosphorylation of RB1 facilitates which of the following:	radio <table border="1"> <tr> <td>20</td> <td>Tumor suppression</td> </tr> <tr> <td>22</td> <td>Entry into the S phase of the cell cycle</td> </tr> <tr> <td>21</td> <td>Inhibition of cell cycle progression</td> </tr> <tr> <td>23</td> <td>Formation of a cyclin D1-CDK4/6 complex</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	20	Tumor suppression	22	Entry into the S phase of the cell cycle	21	Inhibition of cell cycle progression	23	Formation of a cyclin D1-CDK4/6 complex	100	Don't know
20	Tumor suppression												
22	Entry into the S phase of the cell cycle												
21	Inhibition of cell cycle progression												
23	Formation of a cyclin D1-CDK4/6 complex												
100	Don't know												
39	submit_posttest	<p>Fourteen days after you click the submit survey button below you will receive an email with a link to a 5-minute follow-up survey. Upon completion, you will receive your \$100 Amazon.com Gift Card.*</p> <p>On the next screen, we will ask you for feedback on the learning materials.</p> <p>*Amazon.com is not a sponsor of this promotion. Except as required by law, Amazon.com Gift Cards ("GCs") cannot be transferred for value or redeemed for cash. GCs may be</p>	descriptive										

		used only for purchases of eligible goods at Amazon.com or certain of its affiliated websites. For complete terms and conditions, see www.amazon.com/gc-legal . GCs are issued by ACI Gift Cards, Inc., a Washington corporation. All Amazon ®, ™ & © are IP of Amazon.com, Inc. or its affiliates. No expiration date or service fees.											
40	postlearning_material_review_survey_complete	Complete?	dropdown <table border="1"> <tr> <td>0</td> <td>Incomplete</td> </tr> <tr> <td>1</td> <td>Unverified</td> </tr> <tr> <td>2</td> <td>Complete</td> </tr> </table>	0	Incomplete	1	Unverified	2	Complete				
0	Incomplete												
1	Unverified												
2	Complete												
Instrument: Feedback Survey													
41	easy_understanding	The information I viewed was easy to understand.	radio <table border="1"> <tr> <td>1</td> <td>Strongly disagree</td> </tr> <tr> <td>2</td> <td>Disagree</td> </tr> <tr> <td>3</td> <td>Neither agree or disagree</td> </tr> <tr> <td>4</td> <td>Agree</td> </tr> <tr> <td>5</td> <td>Strongly agree</td> </tr> </table>	1	Strongly disagree	2	Disagree	3	Neither agree or disagree	4	Agree	5	Strongly agree
1	Strongly disagree												
2	Disagree												
3	Neither agree or disagree												
4	Agree												
5	Strongly agree												
42	information_confusing	Some of the information I viewed was confusing.	radio <table border="1"> <tr> <td>1</td> <td>Strongly disagree</td> </tr> <tr> <td>2</td> <td>Disagree</td> </tr> <tr> <td>3</td> <td>Neither agree or disagree</td> </tr> <tr> <td>4</td> <td>Agree</td> </tr> <tr> <td>5</td> <td>Strongly agree</td> </tr> </table>	1	Strongly disagree	2	Disagree	3	Neither agree or disagree	4	Agree	5	Strongly agree
1	Strongly disagree												
2	Disagree												
3	Neither agree or disagree												
4	Agree												
5	Strongly agree												
43	information_satisfaction	I am satisfied with the information I viewed.	radio <table border="1"> <tr> <td>1</td> <td>Strongly disagree</td> </tr> <tr> <td>2</td> <td>Disagree</td> </tr> <tr> <td>3</td> <td>Neither agree or disagree</td> </tr> <tr> <td>4</td> <td>Agree</td> </tr> <tr> <td>5</td> <td>Strongly agree</td> </tr> </table>	1	Strongly disagree	2	Disagree	3	Neither agree or disagree	4	Agree	5	Strongly agree
1	Strongly disagree												
2	Disagree												
3	Neither agree or disagree												
4	Agree												
5	Strongly agree												
44	information_new	The information I viewed taught me something new.	radio <table border="1"> <tr> <td>1</td> <td>Strongly disagree</td> </tr> <tr> <td>2</td> <td>Disagree</td> </tr> </table>	1	Strongly disagree	2	Disagree						
1	Strongly disagree												
2	Disagree												

			<table border="1"> <tr> <td>3</td> <td>Neither agree or disagree</td> </tr> <tr> <td>4</td> <td>Agree</td> </tr> <tr> <td>5</td> <td>Strongly agree</td> </tr> </table>	3	Neither agree or disagree	4	Agree	5	Strongly agree				
3	Neither agree or disagree												
4	Agree												
5	Strongly agree												
45	information_openended	Do you have any other thoughts on this material that you would like to share with us?	notes										
46	feedback_survey_complete	Complete?	dropdown <table border="1"> <tr> <td>0</td> <td>Incomplete</td> </tr> <tr> <td>1</td> <td>Unverified</td> </tr> <tr> <td>2</td> <td>Complete</td> </tr> </table>	0	Incomplete	1	Unverified	2	Complete				
0	Incomplete												
1	Unverified												
2	Complete												
Instrument: Knowledge Follow-up Test													
47	followup_fda_approved	Which drug combination is FDA-approved to treat ER+ metastatic breast cancer resistant to letrozole or anastrozole?	radio, Required <table border="1"> <tr> <td>51</td> <td>Erlotinib + exemestane</td> </tr> <tr> <td>52</td> <td>Palbociclib + exemestane</td> </tr> <tr> <td>53</td> <td>Bevacizumab + exemestane</td> </tr> <tr> <td>50</td> <td>Everolimus + exemestane</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	51	Erlotinib + exemestane	52	Palbociclib + exemestane	53	Bevacizumab + exemestane	50	Everolimus + exemestane	100	Don't know
51	Erlotinib + exemestane												
52	Palbociclib + exemestane												
53	Bevacizumab + exemestane												
50	Everolimus + exemestane												
100	Don't know												
48	followup_rb1	Phosphorylation of RB1 facilitates which of the following:	radio, Required <table border="1"> <tr> <td>22</td> <td>Entry into the S phase of the cell cycle</td> </tr> <tr> <td>21</td> <td>Inhibition of cell cycle progression</td> </tr> <tr> <td>23</td> <td>Formation of a Cyclin D1-CDK4/6 complex</td> </tr> <tr> <td>20</td> <td>Tumor suppression</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	22	Entry into the S phase of the cell cycle	21	Inhibition of cell cycle progression	23	Formation of a Cyclin D1-CDK4/6 complex	20	Tumor suppression	100	Don't know
22	Entry into the S phase of the cell cycle												
21	Inhibition of cell cycle progression												
23	Formation of a Cyclin D1-CDK4/6 complex												
20	Tumor suppression												
100	Don't know												
49	followup_palbociclib	Palbociclib is in which of the following drug classes?	radio, Required <table border="1"> <tr> <td>71</td> <td>CDK4/6 inhibitors</td> </tr> <tr> <td>73</td> <td>EGFR inhibitors</td> </tr> <tr> <td>70</td> <td>mTOR inhibitors</td> </tr> <tr> <td>72</td> <td>PI3K inhibitors</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	71	CDK4/6 inhibitors	73	EGFR inhibitors	70	mTOR inhibitors	72	PI3K inhibitors	100	Don't know
71	CDK4/6 inhibitors												
73	EGFR inhibitors												
70	mTOR inhibitors												
72	PI3K inhibitors												
100	Don't know												
50	followup_acquired_mechanisms	Which of the following are ways acquired resistance to endocrine therapy in ER+ breast may occur?	radio, Required <table border="1"> <tr> <td>41</td> <td>Changes in the tumor microenvironment</td> </tr> <tr> <td>42</td> <td>Estrogen receptor mutations</td> </tr> </table>	41	Changes in the tumor microenvironment	42	Estrogen receptor mutations						
41	Changes in the tumor microenvironment												
42	Estrogen receptor mutations												

			<table border="1"> <tr> <td>40</td> <td>Activation of growth factor signaling pathways</td> </tr> <tr> <td>200</td> <td>All of the above</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	40	Activation of growth factor signaling pathways	200	All of the above	100	Don't know				
40	Activation of growth factor signaling pathways												
200	All of the above												
100	Don't know												
51	followup_estrogen	Estrogen is a steroid hormone that controls cell processes like cell division, growth, differentiation, and proliferation.	radio, Required <table border="1"> <tr> <td>1</td> <td>True</td> </tr> <tr> <td>0</td> <td>False</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	1	True	0	False	100	Don't know				
1	True												
0	False												
100	Don't know												
52	followup_fda_accelerated	The FDA granted accelerated approval of which of the following drug combinations for first line or initial endocrine therapy in postmenopausal women with ER+/HER2-negative advanced breast cancer?	radio, Required <table border="1"> <tr> <td>63</td> <td>Everolimus + letrozole</td> </tr> <tr> <td>62</td> <td>Bevacizumab + letrozole</td> </tr> <tr> <td>61</td> <td>Erlotinib + letrozole</td> </tr> <tr> <td>60</td> <td>Palbociclib + letrozole</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	63	Everolimus + letrozole	62	Bevacizumab + letrozole	61	Erlotinib + letrozole	60	Palbociclib + letrozole	100	Don't know
63	Everolimus + letrozole												
62	Bevacizumab + letrozole												
61	Erlotinib + letrozole												
60	Palbociclib + letrozole												
100	Don't know												
53	followup_primary_definition	Please fill in the blank with the correct answer. Primary resistance to endocrine therapy in ER+ breast cancer has been defined as disease progression less than ____ months after treatment in the metastatic setting.	radio, Required <table border="1"> <tr> <td>10</td> <td>10</td> </tr> <tr> <td>8</td> <td>8</td> </tr> <tr> <td>6</td> <td>6</td> </tr> <tr> <td>12</td> <td>12</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	10	10	8	8	6	6	12	12	100	Don't know
10	10												
8	8												
6	6												
12	12												
100	Don't know												
54	followup_primary_mechanisms	Which of the following is a way primary resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer may occur?	radio, Required <table border="1"> <tr> <td>32</td> <td>RB1 amplification</td> </tr> <tr> <td>30</td> <td>Estrogen receptor (ER) amplification</td> </tr> <tr> <td>31</td> <td>Cyclin D1 amplification</td> </tr> <tr> <td>300</td> <td>None of the above</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	32	RB1 amplification	30	Estrogen receptor (ER) amplification	31	Cyclin D1 amplification	300	None of the above	100	Don't know
32	RB1 amplification												
30	Estrogen receptor (ER) amplification												
31	Cyclin D1 amplification												
300	None of the above												
100	Don't know												
55	followup_cdk46_settings	CDK4/6 inhibitors have only been evaluated in the first line setting in breast cancer.	radio, Required <table border="1"> <tr> <td>1</td> <td>True</td> </tr> <tr> <td>0</td> <td>False</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	1	True	0	False	100	Don't know				
1	True												
0	False												
100	Don't know												
56	followup_acquired_definition	Acquired resistance to endocrine therapy in ER+ breast cancer is defined as recurrence at least 6-12 months after completion of adjuvant therapy or disease progression > 6 months after	radio, Required <table border="1"> <tr> <td>1</td> <td>True</td> </tr> <tr> <td>0</td> <td>False</td> </tr> <tr> <td>100</td> <td>Don't know</td> </tr> </table>	1	True	0	False	100	Don't know				
1	True												
0	False												
100	Don't know												

		endocrine therapy initiated in the metastatic setting.										
57	followup_survey_complete	Complete?	dropdown <table border="1"> <tr> <td>0</td> <td>Incomplete</td> </tr> <tr> <td>1</td> <td>Unverified</td> </tr> <tr> <td>2</td> <td>Complete</td> </tr> </table>	0	Incomplete	1	Unverified	2	Complete			
0	Incomplete											
1	Unverified											
2	Complete											
Instrument: Demographics Survey												
58	practice_type	What is your practice type?	radio <table border="1"> <tr> <td>1</td> <td>Academic</td> </tr> <tr> <td>3</td> <td>Community</td> </tr> <tr> <td>4</td> <td>Both</td> </tr> <tr> <td>5</td> <td>Other</td> </tr> </table>	1	Academic	3	Community	4	Both	5	Other	
1	Academic											
3	Community											
4	Both											
5	Other											
59	other_practicetype Show the field ONLY if: [practice_type] = '5'	Other	text									
60	percentage_breastpatients	What is the percentage of patients seen with breast cancer in your practice?	radio <table border="1"> <tr> <td>1</td> <td>Less than 25%</td> </tr> <tr> <td>2</td> <td>25%-50%</td> </tr> <tr> <td>3</td> <td>Greater than 50%</td> </tr> <tr> <td>4</td> <td>Unknown</td> </tr> </table>	1	Less than 25%	2	25%-50%	3	Greater than 50%	4	Unknown	
1	Less than 25%											
2	25%-50%											
3	Greater than 50%											
4	Unknown											
61	age_years	What is your age (years)?	text (integer, Min: 18, Max: 120)									
62	gender	What is your gender?	radio <table border="1"> <tr> <td>1</td> <td>Male</td> </tr> <tr> <td>2</td> <td>Female</td> </tr> <tr> <td>3</td> <td>Prefer not to say</td> </tr> </table>	1	Male	2	Female	3	Prefer not to say			
1	Male											
2	Female											
3	Prefer not to say											
63	ethnicity	Ethnicity:	radio <table border="1"> <tr> <td>1</td> <td>Hispanic or Latino</td> </tr> <tr> <td>2</td> <td>Non-Hispanic</td> </tr> <tr> <td>3</td> <td>Prefer not to say</td> </tr> </table>	1	Hispanic or Latino	2	Non-Hispanic	3	Prefer not to say			
1	Hispanic or Latino											
2	Non-Hispanic											
3	Prefer not to say											
64	race	Race: <i>Check all that apply.</i>	checkbox <table border="1"> <tr> <td>1</td> <td>ethnicity__1</td> <td>White</td> </tr> <tr> <td>3</td> <td>ethnicity__3</td> <td>Black or African American</td> </tr> <tr> <td>4</td> <td>ethnicity__4</td> <td>Native Hawaiian or Other Pacific</td> </tr> </table>	1	ethnicity__1	White	3	ethnicity__3	Black or African American	4	ethnicity__4	Native Hawaiian or Other Pacific
1	ethnicity__1	White										
3	ethnicity__3	Black or African American										
4	ethnicity__4	Native Hawaiian or Other Pacific										

			<table border="1"> <tr> <td></td> <td></td> <td>Islander</td> </tr> <tr> <td>5</td> <td>ethnicity__5</td> <td>Asian</td> </tr> <tr> <td>6</td> <td>ethnicity__6</td> <td>American Indian or Alaska Native</td> </tr> <tr> <td>97</td> <td>ethnicity__97</td> <td>Other</td> </tr> <tr> <td>99</td> <td>ethnicity__99</td> <td>Unknown</td> </tr> <tr> <td>98</td> <td>ethnicity__98</td> <td>Prefer not to say</td> </tr> </table>			Islander	5	ethnicity__5	Asian	6	ethnicity__6	American Indian or Alaska Native	97	ethnicity__97	Other	99	ethnicity__99	Unknown	98	ethnicity__98	Prefer not to say
		Islander																			
5	ethnicity__5	Asian																			
6	ethnicity__6	American Indian or Alaska Native																			
97	ethnicity__97	Other																			
99	ethnicity__99	Unknown																			
98	ethnicity__98	Prefer not to say																			
65	demographics_survey_complete	Complete?	dropdown <table border="1"> <tr> <td>0</td> <td>Incomplete</td> </tr> <tr> <td>1</td> <td>Unverified</td> </tr> <tr> <td>2</td> <td>Complete</td> </tr> </table>	0	Incomplete	1	Unverified	2	Complete												
0	Incomplete																				
1	Unverified																				
2	Complete																				
Instrument: Amazon Gift Card Survey																					
66	send_my_gift_card	I want to receive the \$100 Amazon Gift Card.	yesno, Required <table border="1"> <tr> <td>1</td> <td>Yes</td> </tr> <tr> <td>0</td> <td>No</td> </tr> </table>	1	Yes	0	No														
1	Yes																				
0	No																				
67	vanderbilt_employee Show the field ONLY if: [send_my_gift_card] = '1'	Are you a Vanderbilt University or Vanderbilt University Medical Center employee (faculty, staff, or other)?	yesno, Required <table border="1"> <tr> <td>1</td> <td>Yes</td> </tr> <tr> <td>0</td> <td>No</td> </tr> </table>	1	Yes	0	No														
1	Yes																				
0	No																				
68	ssn Show the field ONLY if: [vanderbilt_employee] = '1'	Please provide your social security number.	text, Required, Identifier																		
69	vu_finance Show the field ONLY if: [send_my_gift_card] = '1'	The Vanderbilt University Finance Department requires us to collect your name and address to issue your gift card. Your information will not be used for anything other than to send the gift card, and it will not be used after completion of the study.	descriptive																		
70	first_name Show the field ONLY if: [send_my_gift_card] = '1'	First Name	text, Required, Identifier																		
71	middle_initial Show the field ONLY if: [send_my_gift_card] = '1'	Middle Initial	text, Identifier																		
72	last_name Show the field ONLY if: [send_my_gift_card] = '1'	Last Name	text, Required, Identifier																		
73	address_1	Address Line 1	text, Required, Identifier																		

	Show the field ONLY if: [send_my_gift_card] = '1'																																																										
74	address_2 Show the field ONLY if: [send_my_gift_card] = '1'	Address Line 2	text, Identifier																																																								
75	city Show the field ONLY if: [send_my_gift_card] = '1'	City	text, Required, Identifier																																																								
76	state Show the field ONLY if: [send_my_gift_card] = '1'	State	dropdown, Required <table border="1"> <tr><td>1</td><td>Alabama</td></tr> <tr><td>2</td><td>Alaska</td></tr> <tr><td>3</td><td>American Samoa</td></tr> <tr><td>4</td><td>Arizona</td></tr> <tr><td>5</td><td>Arkansas</td></tr> <tr><td>6</td><td>California</td></tr> <tr><td>7</td><td>Colorado</td></tr> <tr><td>8</td><td>Connecticut</td></tr> <tr><td>9</td><td>Delaware</td></tr> <tr><td>10</td><td>District of Columbia</td></tr> <tr><td>11</td><td>Florida</td></tr> <tr><td>12</td><td>Georgia</td></tr> <tr><td>13</td><td>Guam</td></tr> <tr><td>14</td><td>Hawaii</td></tr> <tr><td>15</td><td>Idaho</td></tr> <tr><td>16</td><td>Illinois</td></tr> <tr><td>17</td><td>Indiana</td></tr> <tr><td>18</td><td>Iowa</td></tr> <tr><td>19</td><td>Kansas</td></tr> <tr><td>20</td><td>Kentucky</td></tr> <tr><td>21</td><td>Louisiana</td></tr> <tr><td>22</td><td>Maine</td></tr> <tr><td>23</td><td>Maryland</td></tr> <tr><td>24</td><td>Massachusetts</td></tr> <tr><td>25</td><td>Michigan</td></tr> <tr><td>26</td><td>Minnesota</td></tr> <tr><td>27</td><td>Mississippi</td></tr> <tr><td>28</td><td>Missouri</td></tr> </table>	1	Alabama	2	Alaska	3	American Samoa	4	Arizona	5	Arkansas	6	California	7	Colorado	8	Connecticut	9	Delaware	10	District of Columbia	11	Florida	12	Georgia	13	Guam	14	Hawaii	15	Idaho	16	Illinois	17	Indiana	18	Iowa	19	Kansas	20	Kentucky	21	Louisiana	22	Maine	23	Maryland	24	Massachusetts	25	Michigan	26	Minnesota	27	Mississippi	28	Missouri
1	Alabama																																																										
2	Alaska																																																										
3	American Samoa																																																										
4	Arizona																																																										
5	Arkansas																																																										
6	California																																																										
7	Colorado																																																										
8	Connecticut																																																										
9	Delaware																																																										
10	District of Columbia																																																										
11	Florida																																																										
12	Georgia																																																										
13	Guam																																																										
14	Hawaii																																																										
15	Idaho																																																										
16	Illinois																																																										
17	Indiana																																																										
18	Iowa																																																										
19	Kansas																																																										
20	Kentucky																																																										
21	Louisiana																																																										
22	Maine																																																										
23	Maryland																																																										
24	Massachusetts																																																										
25	Michigan																																																										
26	Minnesota																																																										
27	Mississippi																																																										
28	Missouri																																																										

			<table border="1"> <tr><td>29</td><td>Montana</td></tr> <tr><td>30</td><td>Nebraska</td></tr> <tr><td>31</td><td>Nevada</td></tr> <tr><td>32</td><td>New Hampshire</td></tr> <tr><td>33</td><td>New Jersey</td></tr> <tr><td>34</td><td>New Mexico</td></tr> <tr><td>35</td><td>New York</td></tr> <tr><td>36</td><td>North Carolina</td></tr> <tr><td>37</td><td>North Dakota</td></tr> <tr><td>38</td><td>Northern Marianas Islands</td></tr> <tr><td>39</td><td>Ohio</td></tr> <tr><td>40</td><td>Oklahoma</td></tr> <tr><td>41</td><td>Oregon</td></tr> <tr><td>42</td><td>Pennsylvania</td></tr> <tr><td>43</td><td>Puerto Rico</td></tr> <tr><td>44</td><td>Rhode Island</td></tr> <tr><td>45</td><td>South Carolina</td></tr> <tr><td>46</td><td>South Dakota</td></tr> <tr><td>47</td><td>Tennessee</td></tr> <tr><td>48</td><td>Texas</td></tr> <tr><td>49</td><td>Utah</td></tr> <tr><td>50</td><td>Vermont</td></tr> <tr><td>51</td><td>Virginia</td></tr> <tr><td>52</td><td>Virgin Islands</td></tr> <tr><td>53</td><td>Washington</td></tr> <tr><td>54</td><td>West Virginia</td></tr> <tr><td>55</td><td>Wisconsin</td></tr> <tr><td>56</td><td>Wyoming</td></tr> </table>	29	Montana	30	Nebraska	31	Nevada	32	New Hampshire	33	New Jersey	34	New Mexico	35	New York	36	North Carolina	37	North Dakota	38	Northern Marianas Islands	39	Ohio	40	Oklahoma	41	Oregon	42	Pennsylvania	43	Puerto Rico	44	Rhode Island	45	South Carolina	46	South Dakota	47	Tennessee	48	Texas	49	Utah	50	Vermont	51	Virginia	52	Virgin Islands	53	Washington	54	West Virginia	55	Wisconsin	56	Wyoming
29	Montana																																																										
30	Nebraska																																																										
31	Nevada																																																										
32	New Hampshire																																																										
33	New Jersey																																																										
34	New Mexico																																																										
35	New York																																																										
36	North Carolina																																																										
37	North Dakota																																																										
38	Northern Marianas Islands																																																										
39	Ohio																																																										
40	Oklahoma																																																										
41	Oregon																																																										
42	Pennsylvania																																																										
43	Puerto Rico																																																										
44	Rhode Island																																																										
45	South Carolina																																																										
46	South Dakota																																																										
47	Tennessee																																																										
48	Texas																																																										
49	Utah																																																										
50	Vermont																																																										
51	Virginia																																																										
52	Virgin Islands																																																										
53	Washington																																																										
54	West Virginia																																																										
55	Wisconsin																																																										
56	Wyoming																																																										
77	zip Show the field ONLY if: [send_my_gift_card] = '1'	ZIP Code	text, Identifier																																																								
78	md_nonphysician Show the field ONLY if: [send_my_gift_card] = '1' and ([enrollment_arm_1] [role_description] = '2' or [enrollment_arm_1]	I have an M.D. or equivalent degree (e.g., D.O., M.B.B.S)	yesno, Required <table border="1"> <tr><td>1</td><td>Yes</td></tr> <tr><td>0</td><td>No</td></tr> </table>	1	Yes	0	No																																																				
1	Yes																																																										
0	No																																																										

	[role_description] = '3' or [enrollment_arm_1] [role_description] = '4' or [enrollment_arm_1] [role_description] = '5' or [enrollment_arm_1] [role_description] = '6')										
79	country Show the field ONLY if: [send_my_gift_card] = '1' and ([enrollment_arm_1] [role_description] = '1' or [md_nonphysician] = '1')	Are you legally authorized to practice medicine in the United States?	yesno, Required <table border="1"> <tr> <td>1</td> <td>Yes</td> </tr> <tr> <td>0</td> <td>No</td> </tr> </table>	1	Yes	0	No				
1	Yes										
0	No										
80	sunshine_act Show the field ONLY if: [country] = '1' AND [send_my_gift_card] = '1' AND ([enrollment_arm_1] [role_description] = '1' or [md_nonphysician] = '1')	Because this study is funded by Pfizer, we are required to collect information from physicians to fulfill the Sunshine Act reporting requirements to send out the Amazon gift cards. Please fill out the information below to receive your card. Your information will not be used for anything other than to send the gift card, and it will not be used after completion of the study.	descriptive								
81	credential Show the field ONLY if: [country] = '1' and ([enrollment_arm_1] [role_description] = '1' or [md_nonphysician] = '1')	Credential	radio, Required <table border="1"> <tr> <td>1</td> <td>M.D.</td> </tr> <tr> <td>2</td> <td>D.O.</td> </tr> <tr> <td>3</td> <td>M.B.B.S.</td> </tr> <tr> <td>4</td> <td>Other</td> </tr> </table>	1	M.D.	2	D.O.	3	M.B.B.S.	4	Other
1	M.D.										
2	D.O.										
3	M.B.B.S.										
4	Other										
82	other_credential Show the field ONLY if: [credential] = '4'	If you selected other, please explain:	text, Required								
83	npi_id Show the field ONLY if: [country] = '1' and ([enrollment_arm_1] [role_description] = '1' or [md_nonphysician] = '1')	NPI ID <i>Please note that we will not be able to send out the \$100 Amazon gift card without your NPI ID. If you do not remember your NPI ID, please look it up using this link: NPI Registry Search</i>	text (integer), Required, Identifier								
84	amazon_disclaimer_2	*Amazon.com is not a sponsor of this promotion. Except as required by law, Amazon.com Gift Cards ("GCs") cannot be transferred for value or redeemed for cash. GCs may be used only for purchases of eligible goods at Amazon.com	descriptive								

		or certain of its affiliated websites. For complete terms and conditions, see www.amazon.com/gc-legal . GCs are issued by ACI Gift Cards, Inc., a Washington corporation. All Amazon ®, ™ & © are IP of Amazon.com, Inc. or its affiliates. No expiration date or service fees.							
85	amazon_gift_card_complete	Complete?	dropdown <table border="1"> <tr> <td>0</td> <td>Incomplete</td> </tr> <tr> <td>1</td> <td>Unverified</td> </tr> <tr> <td>2</td> <td>Complete</td> </tr> </table>	0	Incomplete	1	Unverified	2	Complete
0	Incomplete								
1	Unverified								
2	Complete								